Occitanie Biotherapies Bioproduction Integrator (OBBI)
keyboard_backspaceBack to Home
Contact
60 rue de Navacelles
34394 Montpellier
France
Chargée d'Affaires
About us
The Occitanie Bioproduction Biotherapy Integrator (OBBI) is a pioneering initiative designed to bridge the gap between academic excellence and industrial application in the fields of biotherapies and bioproduction. Backed by INSERM and the France 2030 National Strategy, OBBI provides biotech and pharmaceutical companies as well as academic partners with unparalleled access to state-of-the-art facilities, cutting-edge technology, and top-tier expertise in organoid and extracellular vesicle (EV) technologies.
OBBI's mission is to accelerate the development and commercialization of innovative biotechnological solutions by fostering strong partnerships between academia and industry. Our comprehensive services and robust infrastructure are tailored to support the bioproduction needs of academic, biotech and pharmaceutical partners, ensuring high-quality, scalable, and standardized solutions.
Business offer
Core Offerings
1. Organoid Bioproduction Services
- Standardized Production: We offer high-throughput and standardized production of organoids derived from both induced pluripotent stem cells (iPSCs) and tissue-specific adult stem cells. Our platforms ensure consistent quality and reproducibility.
- Custom Organoid Development: Tailored organoid models to meet specific research and development needs, including genetic modifications and disease-specific models.
- Biobanking: Access to specialized biobanks containing organoids from healthy individuals and patients with various conditions, including inflammation, cancer, and rare diseases.
2. Extracellular Vesicle (EV) Bioproduction Services
- High-Quality EV Production: Production of research-grade and GMP-like compliant EVs derived from mesenchymal stem cells (MSCs) and iPSCs, ensuring purity and functionality.
- Characterization and Quality Control: Comprehensive characterization services using advanced technologies such as Flow cytometry (NanoFCM) and Super-resolution imaging (ONI), providing detailed analysis of EVs.
- Custom EV Production: Tailored EV production services to meet specific project requirements, including functional characterization and scalability assessments.
3. Comprehensive Bioproduction Support
- Advanced Facilities: Access to cutting-edge bioproduction equipment and expertise at our Montpellier and Toulouse platforms.
- Regulatory Compliance: Support for meeting regulatory standards and compliance for bioproduction, including GMP-like production environments.
- Technology Transfer: Facilitation of technology transfer from academic research to industrial applications, ensuring seamless integration and scalability.
4. Collaborative Research and Development
- Innovation Partnerships: Collaboration opportunities with leading academic and clinical institutions to drive innovation in bioproduction technologies.
- Joint Development Programs: Engagement in multi-stakeholder development programs to address complex bioproduction challenges and accelerate time-to-market.
- Consultation and Training: Expert consultation and training services to support the development of new protocols, optimization of bioproduction processes, and capacity building.
Strategic Advantages:
- Dual Expertise: Unique combination of expertise in organoid and EV technologies, offering comprehensive solutions under one roof.
- State-of-the-Art Infrastructure: Access to advanced bioproduction platforms and specialized biobanks.
- Robust Support Network: Backed by INSERM and regional academic institutions, ensuring high-quality standards and continuous innovation.
- Scalability and Standardization: Focus on scalable and standardized bioproduction processes to meet industrial demands and regulatory requirements.
Get in Touch:
Partner with OBBI to leverage our state-of-the-art bioproduction capabilities and drive innovation in biotherapies. Contact us to discuss how we can support your biotechnological and pharmaceutical projects.
Activities
- Pre-industrial demonstrator
- Cardiology
- Genetic Diseases
- Oncology
- Nervous Central System
- Infectiology
- Immunology
- Ophthalmology
- Inflammation
- Cell origin
- Cell Banking
- IPs
- MSC
- CD34 + HSC cells
- Tissue acquisition
- Target cell isolation
- iPS reprogramming
- Differentiated Cell
- Production Cell
- Safety donor-derived therapies
- Cell modification
- Direct reprogramming
- Cell Activation
- Ex Vivo & In Vivo Strategy
- Ex Vivo & In Vivo Strategy
- CMC/analytical quality assessment, quality control
- Cleaning
- Cross contamination
- Sterility
- Deviations
- Contaminants detection
- Safety for gene-edited cells
- translocation
- anti-nuclease response
- cytokine-independent growth
